TGFBR2 gene-modified exosomes

TGFBR2 gene-modified exosomes are an investigational exosome-based gene therapy developed by Fuwai Hospital, the Chinese Academy of Medical Sciences, and Peking Union Medical College. These exosomes are engineered to overexpress the Transforming Growth Factor Beta Receptor 2 (TGFBR2) on their surface. In the context of carotid artery stenosis, these modified exosomes are designed to function as a molecular "decoy" or "sponge" to sequester circulating Transforming Growth Factor-beta (TGF-β) ligands, particularly TGF-β1 and TGF-β3. By binding to these ligands, the exosomes inhibit the overactivation of the TGF-β signaling pathway in the vascular wall, which is a primary driver of intimal hyperplasia, smooth muscle cell proliferation, and pathological vascular remodeling. This therapeutic approach aims to prevent the recurrence of stenosis following surgical interventions or to slow the progression of atherosclerotic narrowing in the carotid arteries.

Other names

TGFBR2-modified exosomesTGFBR-2-modified exosomesTGFBR 2-modified exosomesTGFBR2-ExosTGFBR-2-ExosTGFBR 2-ExosTGFBR2-overexpressing exosomesTGFBR-2-overexpressing exosomesTGFBR 2-overexpressing exosomes